<SEC-DOCUMENT>0001193125-24-200821.txt : 20240815
<SEC-HEADER>0001193125-24-200821.hdr.sgml : 20240815
<ACCEPTANCE-DATETIME>20240814201625
ACCESSION NUMBER:		0001193125-24-200821
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20240814
FILED AS OF DATE:		20240815
DATE AS OF CHANGE:		20240814

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUTEP Ltd
		CENTRAL INDEX KEY:			0001506184
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35428
		FILM NUMBER:		241210258

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 32, SUITE 32.07 AUSTRALIA SQUARE
		STREET 2:		264 GEORGE STREET
		CITY:			SYDNEY,
		STATE:			C3
		ZIP:			NSW 2000
		BUSINESS PHONE:		612 8315 7003

	MAIL ADDRESS:	
		STREET 1:		LEVEL 32, SUITE 32.07 AUSTRALIA SQUARE
		STREET 2:		264 GEORGE STREET
		CITY:			SYDNEY,
		STATE:			C3
		ZIP:			NSW 2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Prima BioMed Ltd
		DATE OF NAME CHANGE:	20101119
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d886894d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Date as August 14, 2024 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number 001-35428 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>IMMUTEP
LIMITED </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name as Specified in its Charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of
Registrant&#146;s Name) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Level 32, Australia Square </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>264 George Street, Sydney </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NSW 2000, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form 20-F&#8194;&#9746;&#8195;&#8195;&#8195;Form
40-F&#8194;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule
101(b)(1):&#8194;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule
101(b)(7):&#8194;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing
the information to the Commission pursuant to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&#8194;&#9744;&#8195;&#8195;&#8195;No&#8194;&#9746; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;Yes&#148; is marked, indicated below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable. </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description&nbsp;of&nbsp;Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">99.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><A HREF="d886894dex991.htm">Immutep Announces First Participant Dosed in Phase I Study of IMP761, a First in Class Agonist LAG-3 Antibody</A></P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: August 14, 2024 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">IMMUTEP LIMITED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marc Voigt</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Marc Voigt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d886894dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g886894dsp2.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ASX/Media Release </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Announces First Participant Dosed in Phase I Study </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>of IMP761, a First in Class&nbsp;Agonist <FONT STYLE="white-space:nowrap">LAG-3</FONT> Antibody </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>IMP761 is designed to enhance the &#147;brake&#148; function of <FONT STYLE="white-space:nowrap">LAG-3</FONT>
on T cells to restore balance to the immune system and address the underlying cause of many autoimmune diseases</I> </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Safety data from this
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> study anticipated by <FONT STYLE="white-space:nowrap">year-end</FONT> and pharmacokinetics and pharmacodynamics data in first half CY2025</I>
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SYDNEY, AUSTRALIA &#150; 14</B><B></B><B>&nbsp;August </B><B>2024 &#150;</B> Immutep Limited (ASX: IMM; NASDAQ: IMMP)
(&#147;Immutep&#148; or &#147;the Company&#148;), a clinical-stage biotechnology company developing novel <FONT STYLE="white-space:nowrap">LAG-3</FONT> immunotherapies for cancer and autoimmune disease, today announces that the first participant has
been successfully dosed in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> Phase I trial of IMP761. This
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> agonist <FONT STYLE="white-space:nowrap">LAG-3</FONT> antibody is designed to restore balance to the immune system by enhancing the &#147;brake&#148;
function of <FONT STYLE="white-space:nowrap">LAG-3</FONT> to silence dysregulated self-antigen-specific memory T cells that cause many autoimmune diseases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The single and multiple ascending dose, placebo-controlled, double-blind Phase I study is being conducted by the Centre for Human Drug Research (CHDR), a
world-class institute in Leiden, the Netherlands, specializing in cutting-edge early-stage clinical drug research. The study aims to enrol 49 healthy volunteers, to assess safety, pharmacokinetics (PK) and pharmacodynamics (PD). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CHDR will implement its unique keyhole limpet haemocyanin (KLH) challenge model allowing for the evaluation of IMP761&#146;s pharmacodynamic activity at the
earliest stages of clinical development. Immutep anticipates the first safety data from the Phase I study to be available before end of the year with assessment of PK/PD relationships to follow in the first half of CY2025. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The immune checkpoint <FONT STYLE="white-space:nowrap">LAG-3</FONT> has been identified as a promising target for agonist
<FONT STYLE="white-space:nowrap">LAG-3</FONT> immunotherapy to treat rheumatoid arthritis, Type 1 diabetes, and multiple sclerosis, among other autoimmune diseases.<SUP STYLE="font-size:75%; vertical-align:top">1,2,3</SUP> In preclinical studies,
IMP761 has led to a large decrease in inflammatory cytokines and demonstrated its effectiveness in suppressing antigen-specific T cell&#150;mediated immune responses.<SUP STYLE="font-size:75%; vertical-align:top">4,5</SUP> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About IMP761 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IMP761, a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">first-in-class</FONT></FONT> immunosuppressive <FONT STYLE="white-space:nowrap">LAG-3</FONT> agonist antibody, has the potential to address the root cause of many autoimmune diseases by specifically silencing autoimmune
memory T cells that accumulate at disease sites and restoring balance to the immune system. As published in the Journal of Immunology, encouraging <FONT STYLE="white-space:nowrap">pre-clinical</FONT> <I>in vivo </I>and<I> in vitro</I> studies show
IMP761 inhibits peptide-induced T cell proliferation, activation of human primary T cells, and an antigen-specific delayed-type hypersensitivity (DTH) reaction. Additional preclinical data in oligoarticular juvenile idiopathic arthritis <FONT
STYLE="white-space:nowrap">(o-JIA)</FONT> published in Pediatric Research details how IMP761 led to a decrease in a broad spectrum of effector cytokines in just 48 hours. This study also showed children with
<FONT STYLE="white-space:nowrap">o-JIA</FONT> have a skewed <FONT STYLE="white-space:nowrap">LAG-3</FONT> metabolism and suggested they can benefit from agonistic <FONT STYLE="white-space:nowrap">LAG-3</FONT> activity. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g886894dsp2.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Immutep </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep
is a clinical-stage biotechnology company developing novel <FONT STYLE="white-space:nowrap">LAG-3</FONT> immunotherapy for cancer and autoimmune disease. We are pioneers in the understanding and advancement of therapeutics related to Lymphocyte
Activation <FONT STYLE="white-space:nowrap">Gene-3</FONT> <FONT STYLE="white-space:nowrap">(LAG-3),</FONT> and our diversified product portfolio harnesses its unique ability to stimulate or suppress the immune response. Immutep is dedicated to
leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit www.immutep.com. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Australian Investors/Media: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Catherine Strong, Morrow
Sodali </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+61 (0)406 759 268; c.strong@morrowsodali.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Investors/Media: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chris Basta, VP, Investor
Relations and Corporate Communications </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 (631) 318 4000; chris.basta@immutep.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>1. Pedersen, J.M., Hansen, A.S., Skej&oslash;, C. et al. Lymphocyte activation gene 3 is increased and affects cytokine production in rheumatoid arthritis.
Arthritis Res Ther 25, 97 (2023). <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">https://doi.org/10.1186/s13075-023-03073-z</FONT></FONT> </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>2. Jones BE, Maerz MD et al. Fewer <FONT STYLE="white-space:nowrap">LAG-3+</FONT> T Cells in Relapsing-Remitting Multiple Sclerosis and Type 1 Diabetes. J
Immunol. 2022 Feb <FONT STYLE="white-space:nowrap">1;208(3):594-602.</FONT> doi: 10.4049/jimmunol.2100850. Epub 2022 Jan 12. PMID: 35022272; PMCID: PMC8820445. </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>3. Zhou X, Gu Y et al. From bench to bedside: targeting lymphocyte activation gene 3 as a therapeutic strategy for autoimmune diseases. Inflamm Res. 2023
Jun;72(6):1215-1235. doi: <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">10.1007/s00011-023-01742-y.</FONT></FONT></FONT> Epub 2023 Jun 14. PMID: 37314518. </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>4. Mathieu Angin, Chrystelle Brignone, Fr&eacute;d&eacute;ric Triebel; A <FONT STYLE="white-space:nowrap">LAG-3&#150;Specific</FONT> Agonist Antibody for
the Treatment of T Cell&#150;Induced Autoimmune Diseases. J Immunol 15&nbsp;February 2020; 204 (4): 810&#150;818. https://doi.org/10.4049/jimmunol.1900823 </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>5. Sag, E., Demir, S., Aspari, M. et al. Juvenile idiopathic arthritis: lymphocyte activation <FONT STYLE="white-space:nowrap">gene-3</FONT> is a central
immune receptor in children with oligoarticular subtypes. Pediatr Res 90, 744&#150;751 (2021).
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">https://doi.org/10.1038/s41390-021-01588-2</FONT></FONT></FONT> </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Limited</B>, Level&nbsp;32, Australia Square, 264 George Street, Sydney NSW 2000, Australia </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ABN: 90 009 237 889 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g886894dsp2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g886894dsp2.jpg
M_]C_X  02D9)1@ !  $ 8 !@  #__@ ?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP"$  @&!@<&!0@'!P<*"0@*#18.#0P,#1L3%! 6(!PB(1\<
M'QXC*#,K(R8P)AX?+#TM,#4V.3HY(BL_0SXX0S,X.3<!"0H*#0L-&@X.&C<D
M'R0W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W
M-S<W-S<W-__$ :(   $% 0$! 0$!           ! @,$!08'" D*"P$  P$!
M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * $)Q0!S>J>,+>Q
MF:"WB\^13ACNPH/IGO64JB6QRU,3&+LBM9^-&>94N;%E4\[HR20/7'I253I8
MF.)NTFCJXI4FB66-@R,,@@\$5JG<ZT[ZH?3&% !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % &?K=R]GH]U/&<.J?*?0GC^M3)V1G5?+!M'%:-I]AK=U'
M4D@,4>Z0A\^8>!WZ=:PBE)G!2A"J[&GK,(\--'=V)+-(OD_O3NV@ 'C\JN2<
M%=&U1>QUCU)O!%U)+:W-NYRL3!E]LYX_2G3=RL+)N+.LK4ZPH * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M"E9(2BELB?&*904 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M-M#;-JCZYH Q?B=_QZZ=_OO_ "% $?A3QCI6F:##8WCR1RQ%N0A8'+$\8^M
M&!XCU:7Q9KL4=C"[1J/+A3'+>I/I_@* /6-.MA9:;;6H_P"6,:I^0Q0!9H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H HW>D6-
M]*);FV620#;D^E)I-D2IQEJT37%G!=V_D3QAXN/E/M0TGH-Q35F-L["VL$9+
M6)8D8Y('<T)6V",5%61'>:397THDN;=9' P">PI.*>XI0C)W9;5 B*BC"J,
M516RL4X='L+:Z^TPVRI-R=PZ\]:E12U1"IQ3NA;O2;&^E$ES;I(X& 3Z4.*>
MK'*$9;EM$6.,(HPJC 'H*HI:%*'1=/M[D7$-JB2@DAAG/-2HI,A4XIWL6;FU
MAO(##<1B2,]5-4TF4TI*S&6>GVNGJR6L*Q*QR0.YI));!&*CHAM_I5CJD0CO
M;9)E'3<.1]#U%,HR%\"^'E;/V$GV,KX_G0!KV&E6.F(4LK6. -][8N"?J>]
M!J&E6.JQ"*]MDF0=-PY'T/44 9</@K0()!(M@&(.0'=F'Y$XH W\#&* ,2\\
M(:'>RF26P0.>28R4S^5 #K'PIHNG3+-;V*"53E6<ER#ZC)XH YOXG?\ 'KIW
M^^_\A0!+X7\,:1JOABSGO+-7E.\%PQ4GYSUP: .ITW0]-T@'[%:)$3P6ZL?Q
M/- &A0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % $3VT,DBR/
M$C.O1BH)'XT .\I-A3:-K=1C@T -DMH9=OFQ(^WIN4'% #V160JP!4\$$<4
M-BAC@7;$BHOHHP* %,:MG*@YX/'6@!616 !&1UYH  @7. !GDT -:&-XS&T:
ME#U4C@T *(D5%14 5>@ X% "A%#%L#)ZF@!L=O#"S&.)$+<G:H&: 'A0I) Q
MGK0 T1H H"C"]..E #!:6XE\T0QB3.=P49_.@!_E)@#:, Y''0^M "^6NS9M
M&WTQ0 *@4D@8SR?>@!=HW;L<^M $<UM#<8\Z%),=-Z@XH ='%'"@2)%1!T51
M@"@!] !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M\(WK7_/H_P#WVO\ C1R3#V%7L'_"-ZU_SZ/_ -]K_C1R3#V%7L'_  C>M?\
M/H__ 'VO^-'),/85>P?\(WK7_/H__?:_XT<DP]A5[!_PC>M?\^C_ /?:_P"-
M'),/85>P?\(WK7_/H_\ WVO^-'),/85>P?\ "-ZU_P ^C_\ ?:_XT<DP]A5[
M!_PC>M?\^C_]]K_C1R3#V%7L'_"-ZU_SZ/\ ]]K_ (T<DP]A5[!_PC>M?\^C
M_P#?:_XT<DP]A5[!_P (WK7_ #Z/_P!]K_C1R3#V%7L'_"-ZU_SZ/_WVO^-'
M),/85>P?\(WK7_/H_P#WVO\ C1R3#V%7L'_"-ZU_SZ/_ -]K_C1R3#V%7L'_
M  C>M?\ /H__ 'VO^-'),/85>P?\(WK7_/H__?:_XT<DP]A5[!_PC>M?\^C_
M /?:_P"-'),/85>P?\(WK7_/H_\ WVO^-'),/85>P?\ "-ZU_P ^C_\ ?:_X
MT<DP]A5[!_PC>M?\^C_]]K_C1R3#V%7L'_"-ZU_SZ/\ ]]K_ (T<DP]A5[!_
MPC>M?\^C_P#?:_XT<DP]A5[!_P (WK7_ #Z/_P!]K_C1R3#V%7L'_"-ZU_SZ
M/_WVO^-'),/85>P?\(WK7_/H_P#WVO\ C1R3#V%7L'_"-ZU_SZ/_ -]K_C1R
M3#V%7L'_  C>M?\ /H__ 'VO^-'),/85>P?\(WK7_/H__?:_XT<DP]A5[!_P
MC>M?\^C_ /?:_P"-'),/85>P?\(WK7_/H_\ WVO^-'),/85>P?\ "-ZU_P ^
MC_\ ?:_XT<DP]A5[!_PC>M?\^C_]]K_C1R3#V%7L'_"-ZU_SZ/\ ]]K_ (T<
MDP]A5[!_PC>M?\^C_P#?:_XT<DP]A5[!_P (WK7_ #Z/_P!]K_C1R3#V%7L'
M_"-ZU_SZ/_WVO^-'),/85>P?\(WK7_/H_P#WVO\ C1R3#V%7L'_"-ZU_SZ/_
M -]K_C1R3#V%7L'_  C>M?\ /H__ 'VO^-'),/85>P?\(WK7_/H__?:_XT<D
MP]A5[!_PC>M?\^C_ /?:_P"-'),/85>P?\(WK7_/H_\ WVO^-'),/85>P?\
M"-ZU_P ^C_\ ?:_XT<DP]A5[!_PC>M?\^C_]]K_C1R3#V%7L'_"-ZU_SZ/\
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M(WK7_/H__?:_XT<DP]A5[!_PC>M?\^C_ /?:_P"-'),/85>P?\(WK7_/H_\
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M>M?\^C_]]K_C1R3#V%7L'_"-ZU_SZ/\ ]]K_ (T<DP]A5['I==9ZC"@04 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
B% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
